FABP7 and nonpapillary renal cell carcinoma: To evaluate the efficacy of FABP7 as a biomarker, we retrospectively reviewed the clinical data of 40 patients with metastatic ccRCC who had undergone nephrectomy, followed by systemic therapy using either a cytokine, VEGF-TKIs, or mTOR inhibitors in Yamaguchi University Hospital.